The Benefits of US Biotechs Conducting Clinical Trials in Australia

Australia has quickly become a top destination for US biotech companies conducting early-phase clinical trials. With streamlined regulatory pathways, cost efficiency, and robust government support, the region offers a powerful combination of speed, quality, and value for early-stage drug development.

In this whitepaper, we explore the key advantages of running trials in Australia. From fast ethics approvals via the Clinical Trial Notification (CTN) scheme to alignment with FDA and EMA expectations, Australia provides a globally recognised regulatory environment that accelerates timelines and ensures data integrity.

One of the most compelling benefits is the Australian Government’s R&D tax incentive—offering rebates of up to 43.5% for eligible companies. This, combined with Australia’s high-quality clinical infrastructure, experienced investigators, and access to diverse patient populations (including those with rare diseases), makes it an ideal setting for early-phase and decentralized clinical trials.

Southern Star Research (SSR) acts as a trusted partner for biotech companies navigating the region’s clinical trial landscape. With deep local expertise and end-to-end CRO services, Southern Star Research ensures efficient regulatory planning, reliable data collection, and successful trial execution across therapeutic areas such as oncology, infectious diseases, and RNA therapies.

For US biotechs seeking an agile, cost-effective, and scientifically rigorous environment to conduct early-phase clinical research, Australia is the clear choice.